Insights for Payers—RMS Treatment Considerations and Real-World Evidence Based on a Milliman Actuarial Analysis


Science & Innovation Theater Webinar 

Recorded on October 26, 2016 

Sponsored by Biogen 

Click here to download PDF of presentation 

Please also see the related white paper at this link: 



The presentation will provide an overview of relapsing multiple sclerosis (RMS) treatment considerations and pharmacoeconomic insights for MS, as reported in a 2016 Milliman commercial claims data analysis. 

This is a non-CME program and is intended only for members of formulary committees or similar entities pursuant to Section 114 of the FDA Modernization Act.

This webinar is sponsored and developed by Biogen. The content of the Science & Innovation Theater Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of the Academy of Managed Care Pharmacy.  

Sponsored by: